Podcasts about patients

"Wie wir heute leben, macht uns krank", ist eine These von Dr. Michael Lehnert. Der Berliner ist Sportmediziner, Handchirurg und Orthopäde und sieht täglich bei seinen Patient*innen die Auswirkungen einer falschen Haltung. Stundenlanges Sitzen oder das verkrafte Abwärtsblicken aufs Handy überfordern den Körper. Das Handy weglegen - das allein reicht bei den meisten schon nicht mehr, um die Schmerzen zu lindern. Lehnert zeigt, wie man Warnsignale frühzeitig erkennt und welche Übungen als Selbsthilfe helfen.

Amid the Trump administration's crackdown on immigration, there’s been an uptick in ICE presence in hospitals across the country. At Adventist Health White Memorial hospital in Boyle Heights, doctors say that hospital administrators have even allowed immigration agents to interfere with patients’ medical care. LAist correspondent Jill Replogle has been reporting on the hospital. She tells us how healthcare workers are dealing with immigration agents showing up in emergency rooms and clinics, what it says about patients' rights to privacy and the treatment of immigrants in hospitals moving forward. This LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autos Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.

Sitting in for Thom Hartmann is guest-host Jefferson Smith of the Democracy Nerd podcast. Former Chief Technology Officer for the US Department of Health and Human Services, Susannah Fox explains her new book, "Rebel Health: A Field Guide to the Patient-Led Revolution in Medical Care."See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Amid the Trump administration's crackdown on immigration, there’s been an uptick in ICE presence in hospitals across the country. At Adventist Health White Memorial hospital in Boyle Heights, doctors say that hospital administrators have even allowed immigration agents to interfere with patients’ medical care. LAist correspondent Jill Replogle has been reporting on the hospital. She tells us how healthcare workers are dealing with immigration agents showing up in emergency rooms and clinics, what it says about patients' rights to privacy and the treatment of immigrants in hospitals moving forward. This LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autos Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.

Amid the Trump administration's crackdown on immigration, there’s been an uptick in ICE presence in hospitals across the country. At Adventist Health White Memorial hospital in Boyle Heights, doctors say that hospital administrators have even allowed immigration agents to interfere with patients’ medical care. LAist correspondent Jill Replogle has been reporting on the hospital. She tells us how healthcare workers are dealing with immigration agents showing up in emergency rooms and clinics, what it says about patients' rights to privacy and the treatment of immigrants in hospitals moving forward. This LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autos Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.

Amid the Trump administration's crackdown on immigration, there’s been an uptick in ICE presence in hospitals across the country. At Adventist Health White Memorial hospital in Boyle Heights, doctors say that hospital administrators have even allowed immigration agents to interfere with patients’ medical care. LAist correspondent Jill Replogle has been reporting on the hospital. She tells us how healthcare workers are dealing with immigration agents showing up in emergency rooms and clinics, what it says about patients' rights to privacy and the treatment of immigrants in hospitals moving forward. This LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autos Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.Support LAist Today: https://LAist.com/join

Stevi got into Primal, then keto, then carnivore after seeing family members suffer, and dealing with her own weight issues. Carnivore got her through 2 pregnancies, got her BMI to normal levels, gave her back her brain power, and has allowed her to get through food addictions and help others to do the same. Stevi works with those that have autoimmune issues, on the AIP diet, with carnivore leaning and help them to figure out which foods trigger those issues. Stevi also created her own salad dressing company for those that need AIP options for seasonings, called Hearty Sauces. Instagram: https://www.instagram.com/carnivoreinthesuburb/ https://www.instagram.com/heartysauces/ Website: www.heartysauces.com Timestamps: 00:00 Trailer 00:35 Introduction 03:28 Journey to nutrition awareness 07:17 Nuance in carnivore 12:24 From keto to autoimmune coaching 15:39 Prioritizing sleep for optimal health 19:37 Balance and personalized nutrition 21:07 Patient advocacy and medical decisions 25:14 Gut healing and carnivore mistakes 27:58 Modern snacking habits 31:45 Processing and protein powder debate 36:22 Breastfeeding, brain size, and diet 38:56 Making healthy eating fit lifestyle 41:06 Value of expert guidance Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

Mechanical ventilation doesn't have to feel like wizardry. In this podcast episode, we strip it back to what really matters—simple mental models, clean decision-making, and an approach that works whether you're in the back of a helicopter, a tight ambulance box, or a chaotic ED bay. We walk through the foundational concepts and the "why" behind each knob you touch. Then we zoom in on the Hamilton T1, the vent many of us love, hate, and still rely on every single shift. We cover what the T1 gets right, where people get tripped up, and how to let the machine work with you instead of against you. If you've ever wished mechanical ventilation felt less like memorizing settings and more like understanding physiology in motion, this episode will tighten up your practice and give you tools you can use on your very next flight or transport. Get CE hours for our podcast episodes HERE! -------------------------------------------- Twitter @heavyhelmet Facebook @heavyliesthehelmet Instagram @heavyliesthehelmet Website heavyliesthehelmet.com Email contact@heavyliesthehelmet.com Disclaimer: Heavy Lies the Helmet's content is for educational purposes only and does not constitute medical advice. Always follow local guidelines and consult qualified professionals before applying any information. The hosts and guests are not responsible for errors, omissions, or outcomes. Views expressed are their own and do not reflect their employers or affiliates. --------------------------------------------  Crystals VIP by From The Dust | https://soundcloud.com/ftdmusic Music promoted by https://www.free-stock-music.com

This week we review the topic of mitral annular disjunction ("MAD") and the possible association with ventricular arrhythmia or sudden death in the connective tissue disease patient. Is there a 'cut off' distance above which patients deserve more significant arrhythmia surveillance? What is the best way to measure the MAD distance? Can patients with low MAD distances have lower degrees or even no arrhythmic surveillance? How often should this distance be measured on CMR and can an echo measurement provide similar data? Dr. Daniel Castellanos, the first author of this work and Assistant Professor of Pediatrics at Harvard Medical School shares his deep insights this week.DOI: 10.1016/j.jocmr.2025.101954

Amid the Trump administration's crackdown on immigration, there’s been an uptick in ICE presence in hospitals across the country. At Adventist Health White Memorial hospital in Boyle Heights, doctors say that hospital administrators have even allowed immigration agents to interfere with patients’ medical care. LAist correspondent Jill Replogle has been reporting on the hospital. She tells us how healthcare workers are dealing with immigration agents showing up in emergency rooms and clinics, what it says about patients' rights to privacy and the treatment of immigrants in hospitals moving forward. This LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autos Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

On this episode of the podcast, Missouri Congressman Eric Burlison discussed his proposal for a new healthcare account, the MAHA account, which would function like a supercharged Health Savings Account (HSA), allowing individuals to save up to $25,000 tax-free annually for health insurance and wellness expenses.He emphasized the need for a new solution to address healthcare affordability issues, criticizing Obamacare's preserve incentives. The Missouri Republican also highlighted the role of pharmacy benefit managers (PBMs) in driving up pharmaceutical costs and advocated for giving patients direct choice. He believes MAHA accounts could be implemented by March 2026, potentially reducing healthcare costs and increasing consumer options.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Amid the Trump administration's crackdown on immigration, there’s been an uptick in ICE presence in hospitals across the country. At Adventist Health White Memorial hospital in Boyle Heights, doctors say that hospital administrators have even allowed immigration agents to interfere with patients’ medical care. LAist correspondent Jill Replogle has been reporting on the hospital. She tells us how healthcare workers are dealing with immigration agents showing up in emergency rooms and clinics, what it says about patients' rights to privacy and the treatment of immigrants in hospitals moving forward. This LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autos Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.

In this powerful episode, Dr. Howland talks with Meagan Skidmore, a fellow author and costar on Writer's Island. Meagan shares her story of being the mother of transgender child and how that has made her a better parent. This is an episode about the power of love and acceptance despite our differences.

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor, including the following topics: Introduction: Assessment of HER2 Status (0:00) Case: An otherwise healthy woman in her early 50s with HER2-positive metastatic gallbladder cancer and multiple intrahepatic metastases — Jeremy Lorber, MD (7:33) Case: A man in his late 60s with HER2-low metastatic gallbladder cancer — Brian P Mulherin, MD (11:58) Data Review: Biliary Tract Cancers (18:19) Case: A man in his mid 50s with HER2-positive metastatic rectal cancer — Sunil Gandhi, MD (26:25) Case: A woman in her early 60s with recurrent HER2-positive rectal cancer — Ranju Gupta, MD (31:31) Data Review: Colorectal Cancer (34:16) Case: An otherwise healthy man in his mid 50s with HER2-positive metastatic gastroesophageal junction cancer and several metastatic liver lesions — Shachar Peles, MD (38:06) Case: A man in his early 60s with recurrent HER2-positive, claudin 18.2-positive metastatic esophageal cancer — Susmitha Apuri, MD (43:21) Data Review: Gastroesophageal Cancer (46:55) Case: A man in his early 60s with HER2-positive esophageal cancer and isolated brain metastases — Priya Rudolph, MD, PhD (50:07) CME information and select publications

Most people only see the blood sugar graph… but not the battles behind every number. This National Diabetes Awareness Month, Matt goes live on KUSI News to reveal what life with Type 1 really looks like—and howthousands are learning to MASTER it, not just manage it.>> ENJOY!Grab your Ultimate Guide To T1D Weight Loss here: https://t1dbootcamp.com/uwlgPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

The latest Nursing Standard podcast discusses an NHS trust's decision to restrict bank shifts, news of a chief nurse being reinstated to her role following suspension, and free tea and coffee being scrapped for one trust's staff, among other hot topics.For more episodes of the Nursing Standard podcast, visit rcni.com/podcast Hosted on Acast. See acast.com/privacy for more information.

Community: The Hidden Engine Behind Every Successful Cash PT Clinic In this episode, Doc Danny Matta shares the single theme that stood out after spending a full week embedded inside four different cash-based and boutique rehab businesses in Washington, D.C.: community. He breaks down why community involvement is the ultimate competitive advantage, how it fuels long-term growth, and why you can't fake it—or skip it—if you want a thriving practice. Quick Ask If this episode challenges the way you think about growing your practice, share it with another clinician who needs to hear it—and tag @dannymattaPT so he can reshare it. Episode Summary Documentation burden solved: AI scribes like Clair eliminate notes so you stay present with patients. The D.C. trip: Danny spent full days inside four thriving clinics, observing their operations, patients, and culture. One takeaway: Every successful clinic shared the same backbone—deep community involvement. Community is earned: You can't fake participation; you must show up consistently and authentically. Clinician examples: Pilates studios, running groups, boutique fitness hubs—all thriving because owners live inside the communities they serve. Your niche = your tribe: If you're not plugged into your niche's world, someone else will be. Give more than you take: Communities reward contributors, not extractors. Lessons & Takeaways Community drives retention: Patients stick when they feel connected—not just treated. You must participate: Go to races, gyms, events, tournaments; be where your niche actually lives. You can't fake interest: If you hate running, don't try to be a running PT—hire someone who loves it. Your presence builds reputation: When people see you consistently, trust builds effortlessly. Local involvement compounds: Over years, you become a recognizable part of your city's health ecosystem. Mindset & Motivation Play the long game: Community isn't built in 30 days—it's built through years of showing up. Pick what you enjoy: Your energy is higher and your authenticity obvious when you actually like the niche you serve. Give first, receive later: The tribe takes care of contributors. Local roots matter: Even if you grew up moving around (like Danny), you can build community intentionally. Community is a moat: No amount of marketing can replace genuine involvement. Pro Tips for Clinic Owners Use an AI scribe: Tools like Clair free up hours so you can deepen relationships, not write notes. Engage where your niche lives: Join their gyms, events, groups, classes—don't just "network." Participate. Host or join local events: Run groups, wellness fairs, meetups, workshops, boutique fitness partnerships. Be a connector: Bring other local business owners together—become the hub. Hire for gaps: If you don't love a niche, hire clinicians who genuinely do. Notable Quotes "You can't fake community. People know when you're genuinely involved versus when you're just showing up for patients." "If you pour into your community, your community will take care of you." "Some of these clinics are like local celebrities in their niche—because they've earned it." "Pick the community you enjoy. You'll never stick with something you secretly hate." Action Items Identify one niche you naturally enjoy being around. Join three of their events or classes this month. Start conversations—not pitches—with people in your niche community. Partner with one local gym, coach, or instructor. Evaluate your schedule and offload notes with Clair so you can spend more time engaging locally. Programs Mentioned PT Biz Part-Time to Full-Time 5-Day Challenge (Free): Get crystal clear on how to replace your income and go full time. Join here. Resources & Links PT Biz Website Free 5-Day Challenge MeetClair AI — Free 7-day trial About the Host: Doc Danny Matta — physical therapist, entrepreneur, founder of PT Biz and Athlete's Potential. He's helped over 1,000 clinicians start, grow, and scale successful cash practices and is committed to developing leaders who build meaningful, community-rooted businesses.

Join Elevated GP: www.theelevatedgp.com Net32.com  Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram His interdisciplinary approach to dentistry is founded in both empirical research and clinical experience. He attended the University of Washington for both his undergraduate and graduate studies where he received his D.D.S. degree in 1995 and an M.S.D. and certificate in Prosthodontics in 1998. For his entire career, Dr. Kinzer has been committed to furthering the art and science of dental education. His unique ability to impart complex clinical processes in a logical, systematic and clear methodology differentiates him from other Prosthodontists and makes him a highly regarded educator nationally and internationally. He is a full-time teaching faculty at Spear Education in Scottsdale, AZ. where he is also resides as the Faculty Chairman and Director of Curriculum and Campus Education. Dr. Kinzer is an Affiliate Assistant Professor in the Graduate Prosthodontics Department at the University of Washington School of Dentistry and an Adjunct Faculty at Arizona School of Dentistry and Oral Health. Dr. Kinzer is a member of many professional organizations including the American Academy of Restorative Dentistry and the American Academy of Esthetic Dentistry, of which he is currently the sitting President. He serves on the editorial review board for several recognized dental publications and has written numerous articles and chapters for dental publication. He has been honored with the American College of Prosthodontics Achievement Award and in 2018, he received the Saul Schluger Memorial Award for Excellence in Diagnosis and Treatment Planning from the Seattle Study Club. In 2022 he was inducted into the World's Top 100 Doctors as part of the Interdisciplinary Cohort. In his free time, Gregg cherishes spending time his wife Jill and their 6 children. He enjoys anything that he can do outside: golfing, hiking, running, skiing, and biking, in addition to a nice glass of wine.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Private equity is reshaping healthcare—but at what cost? In this eye-opening episode of Beyond the Mask, Sharon and Jeremy welcome back Daniel King, DNP, MNA, CRNA, CPPS, CNE and Jennifer Banek, MSN, MHA, CRNA for a candid conversation about how private equity ownership affects anesthesia and beyond. They explain how investor-driven models prioritize profit over patient care, share real-world stories of unsafe conditions and staff cutbacks, and reveal how financial engineering often leaves hospitals saddled with debt. Keep in mind, not all private equity is bad or creates the problems we discuss in this episode. Here's some of what you'll hear in this episode:

In this episode, Dr. Peggy Greco of Nemours Children's Health and Rachel Hamilton of NRC Health, discuss how their organizations use equity centered data, communication tools, and patient voice to close experience gaps and improve outcomes for children and families.This episide is sponsored by NRC Health.

Relapsed/refractory follicular lymphoma (R/R FL) is challenging to treat, requiring thoughtful clinical decision-making during treatment selection and sequencing. In this episode, CANCER BUZZ speaks with Benjamin Heyman, MD, hematologist and clinical associate professor at City of Hope, about the importance of individualized care, shared decision-making, clinical trial referrals, and multidisciplinary collaboration. CANCER BUZZ also speaks with Laurie Adami, patient advocate with R/R FL, about her real-world experience with multiple lines of therapy, clinical trials, and patient advocacy.     "There are lots of options available, which is really great for patients, so you get to have a good conversation with patients about what they value." - Benjamin Heyman, MD   "The medications you receive in clinical trials may not be the standard of care today, but it may be the standard of care 5 years from now." - Benjamin Heyman, MD   "Patient advocacy organizations have patients that can talk to you. They know what you're talking about. They're on the road ahead of you." - Laurie Adami   Guest:                    Benjamin Heyman, MD Hematologist Clinical Associate Professor City of Hope San Diego, CA   Laurie Adami R/R FL Patient Advocate Los Angeles, LA Received care at UCLA Lymphoma Program   Additional Reading/Sources ACCC Follicular Lymphoma Effective Practice Guide: Multidisciplinary Approaches to Treating Patients With R/R FL Putting Guidance Into Practice: Real-World Approaches to Relapsed/Refractory Folicular Lymphoma ACCC's Community Oncology Research Institute

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer. Key topics included: The definition and characteristics of high-risk non-muscle invasive bladder cancer. Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment. The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach. Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy. Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes. Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology! #NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

Synopsis: In a conversation rich with strategic insight, Coya Therapeutics CEO Arun Swaminathan unpacks the intersections of scientific innovation, business development discipline, and capital-efficient execution that define today's most resilient biotechs. With a 25-year foundation spanning R&D, clinical pharmacology, marketing, and BD, Arun offers investors a rare systems-level lens on how neurodegenerative programs progress from hypothesis to value inflection. Through his dialogue with host Alok Tayi, he breaks down Coya's differentiated Treg-modulating platform and the data emerging across ALS, FTD, and Alzheimer's. He explains why Coya's dual-mechanism approach—restoring regulatory T-cell function while reshaping the neuroinflammatory environment—is uniquely poised to change patient trajectories. Arun also delves into the structural logic behind Coya's partnership with Dr. Reddy's, demonstrating how complementary strengths in manufacturing, commercialization, and regulatory strategy can dramatically shift both timelines and capital needs. For investors tracking macro trends, he contextualizes shifting interest rates, pipeline gaps, and rising M&A momentum—and why 2026 may mark the beginning of a healthier biotech cycle. A must-listen for anyone evaluating platform durability, risk mitigation strategies, and next-generation neurodegenerative therapeutics. Biography: Arun Swaminathan, Ph.D., has over 20 years of hands-on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. He possesses a demonstrated history of prospecting, evaluating, structuring, and closing company validating transactions that augment both organizational and shareholder value. Prior to joining Coya, Arun served as Chief Business Officer (CBO) for Actinium Pharmaceuticals (NYSE: ATNM) where he was responsible for all business development. Within 1 year of joining Actinium, he successfully moved forward negotiations to closure and executed a $452M deal with $35M upfront. Prior to Actinium, he was the CBO at Alteogen (196170.KQ) where he spearheaded over $6B in deals, including deals with two of the top 10 global pharma companies and a $1B+ deal within the first year of assuming the role of CBO. Prior to this, he co-founded and served as CEO of Lynkogen Inc, a pre-clinical stage biotech. Arun began his career in clinical development and commercial roles of increasing responsibility at BristolMyers Squibb and Covance. He obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh.

Does cannabis use have any effect, good or bad, on Orthopaedic Surgery? It's a question we, as a Sports Medicine community, hear increasingly frequently from our patients but so far don't have great data to provide sound advice. We welcome Dr. Grant Hogue who has studied this extensively across several disciplines of Orthopaedic Surgery. He presents his work with his colleagues at Boston Children's Hospital looking specifically at adverse effects of marijuana use on ACL reconstruction recovery.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

In this episode of The Spine Pod, hosts Courtney Schutze and Brady Riesgraf sit down with Dr. Kamal Woods, a double fellowship-trained surgeon in both orthopedics and neurosurgery, and founder of Vertrae® in Miamisburg, Ohio.   Dr. Woods received his medical degree from Loma Linda University School of Medicine and completed a fellowship in minimally invasive and complex spine surgery from Cedars‑Sinai Medical Center. He later earned his MBA from Johns Hopkins Carey Business School, further deepening his understanding of the complex healthcare ecosystem and how to improve it. Since then, he has gone on to build a patient-centered practice rooted in the belief that one size does not fit all when it comes to spine care. Whether a patient needs a non‑surgical treatment, minimally invasive surgery, or motion‑preserving option, the goal remains the same: restore mobility, alleviate pain, and help patients return to what they love most.   Throughout the episode, Dr. Woods shares his philosophy of combining surgical precision with compassionate, personalized care. He also discusses the importance of having a full “toolbox” of treatments, from conservative care and robotic‑assisted techniques to artificial disc replacement, and why patient education and shared decision‑making are essential. He goes on to share how his background, far from conventional, has shaped his patient‑first mindset and his vision for modern spine care.   In this episode, you'll learn: Why motion preservation is more than a trend, it's about protecting function and long-term quality of life. How insurance and reimbursement barriers can impact patient care, and the changes needed to move the field forward. Why outpatient, motion-preserving spine care is gaining momentum and what it takes to build a successful model. How Dr. Woods prioritizes patients through individualized treatment plans for those dealing with chronic leg and back pain. Why enabling technologies such as navigation and robotics are expanding into more surgical facilities. How Vertrae® is driving local innovation through education, community events, and an empowering patient-centered care model.   Drawing on his childhood roots in Saint Vincent, his surgical training in California, and the practice he's built in Ohio, Dr. Woods is shaping an innovative spine care model centered on motion preservation—designed to help patients return to the activities they love, all in one integrated setting. Whether you're a surgeon focused on emerging technologies, an industry professional tracking care trends, or a patient seeking clarity in a crowded spine landscape, this episode delivers compelling insights on how treatment pathways are shifting and how modern practice models are evolving.   Learn more about Dr. Woods: Vertrae: https://vertrae.com/ LinkedIn: https://www.linkedin.com/in/kamal-woods-md-mba-89172682/ Instagram: https://www.instagram.com/vertrae.inc/?hl=en Facebook: https://www.facebook.com/KamalWoodsMD YouTube: https://www.youtube.com/ ⁨@vertrae360⁩   You can find The Spine Pod on all Podcast Streaming Platforms, including: YouTube: https://www.youtube.com/@TheSpinePod Spotify: https://open.spotify.com/show/0DBzWfVt1ExQE0qTjhOERa?si=EEBPwQgRQSujyZsaXnJagA Apple Podcasts: https://podcasts.apple.com/us/podcast/the-spine-pod/id1745442311 Amazon Music: https://music.amazon.com/podcasts/98fd41ad-75ee-4371-bb70-c5b274324a47/the-spine-pod?ref=dm_sh_kmfvSHB5iY109GDslhiJul22E iHeart Radio: https://www.iheart.com/podcast/269-the-spine-pod-174320414?cmp=ios_share&sc=ios_social_share&pr=false&autoplay=true Follow The Spine Pod to learn more about the latest episodes and happenings in the world of motion preservation: ⁠ Facebook: https://www.facebook.com/profile.php?... Instagram: https://www.instagram.com/thespinepod... TikTok: www.tiktok.com/@thespinepod The information in this podcast is for educational and informational purposes only and is not intended as medical advice.

Do you have a “hopeless” retained root you're ready to extract? Think implants, dentures, or bridges are the only way forward? What if there's a way to save that tooth — predictably and biologically? In this episode, Dr. Vala Seif shares his experience with the Surgical Extrusion Technique — a game-changing approach that lets you reposition the root coronally to regain ferrule and restore teeth once thought impossible to save. Jaz and Dr. Seif dive into case selection, atraumatic technique, stabilization, and timing, all guided by Dr. Seif's own SAFE/SEIF Protocol, developed from over 200 successful cases. https://youtu.be/2TyodqgAP9w Watch PDP249 on YouTube Protrusive Dental Pearl: When checking a ferrule, consider height, thickness, and location of functional load. Upper teeth: prioritize palatal ferrule. Lower teeth: prioritize buccal. Tip: do a partial surgical extrusion, rotate the tooth 180°, then stabilize. Key Takeaways Surgical extrusion is a technique-sensitive procedure that requires careful planning. Case selection is crucial for the success of surgical extrusion. A crown-root ratio of 1:1 is ideal for surgical extrusion. Patients are often more cooperative when they see surgical extrusion as their last chance to save a tooth. Surgical extrusion can be more efficient than orthodontic extrusion in certain cases. The importance of ferrule in dental restorations cannot be overstated. Proper case selection is crucial for successful outcomes. Atraumatic techniques are essential for preserving tooth structure. The 'Safe Protocol' offers a structured approach to surgical extrusion. Patient communication is key to managing expectations. Flowable composite is preferred for tooth fixation post-extraction. Understanding root morphology is important for successful extractions. Highlights of this episode: 00:00 Surgical Extrusion Podcast Teaser 01:07 Introduction 02:38 Protrusive Dental Pearl 05:53 Interview with Dr. Vala Seif 08:57 Definition and Philosophy of Surgical Extrusion 15:30 Indications, Case Selection, and Root Morphology 21:37 Comparing Surgical and Orthodontic Extrusion 25:54 Crown Lengthening Drawbacks 28:39 Occlusal Considerations 33:53 Midroll 37:16 Definition and Importance of the Ferrule 43:07 Clinical Protocols and Fixation Methods 01:00:01 Post-Extrusion Care and Final Restoration 01:05:04 Learning More and Final Thoughts 01:09:29 Outro Further Learning: Instagram: @extrusionmaster — case examples, papers, and protocol updates. Online and in-person courses in development (Europe + global access). Loved this episode? Don't miss “How to Save ‘Hopeless' Teeth with the Surgical Extrusion Technique” – PDP061 #PDPMainEpisodes #OralSurgeryandOralMedicine #OrthoRestorative This episode is eligible for 1 CE credit via the quiz on Protrusive Guidance.  This episode meets GDC Outcomes C. AGD Subject Code: 310 ORAL AND MAXILLOFACIAL SURGERY Aim: To understand the biological and clinical principles of surgical extrusion as a conservative alternative to orthodontic extrusion or crown lengthening for managing structurally compromised teeth. Dentists will be able to - Identify suitable clinical cases for surgical extrusion, including correct root morphology and crown–root ratios. Describe the step-by-step SAFE Protocol for atraumatic surgical extrusion, fixation, and timing of endodontic treatment. Evaluate the advantages, limitations, and biomechanical considerations of surgical extrusion compared with orthodontic extrusion and crown lengthening.

Jeffrey W Meeusen, Xin Yi, Steven W Cotten, Jacob B Nielsen, Leslie J Donato, Patricia M Jones, Alagar R Muthukumar, Rafael Zubirán, Alan T Remaley, Jing Cao, Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol, Clinical Chemistry, Volume 71, Issue 11, November 2025, Pages 1138–1146, https://doi.org/10.1093/clinchem/hvaf099

In this episode of the ESCRS IME podcast series on simultaneous vision IOLs, Drs. Francesco Carones and Andrea Janeková explore the selection and benefits of these lenses for presbyopia correction. They highlight the importance of tailoring lens choices to each patient's lifestyle and ocular conditions, managing expectations during the adaptation period, and ensuring thorough screening and postoperative care to maximize patient satisfaction. Don't miss this insightful episode and be sure to check out the other expert-led podcasts in the series! Independent medical education supported by Alcon (Gold), J&J (Gold), B+L (Silver), Zeiss (Bronze).

About this episode: Robotic telesurgery allows providers to conduct minimally invasive surgeries across long distances, reaching remote communities. In this episode: Binita Ashar, a surgeon with a background in policy, discusses the revolutionary role this technology can play in medicine and what issues need to be addressed—from cost to cybersecurity—in order to greenlight more procedures in the United States. Guests: Binita Ashar, MD, MBA, is a general surgeon who previously served as the Director of the FDA's Office of Surgical and Infection Control Devices. She also serves on the board of the Society of Robotic Surgery. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: Exclusive look at groundbreaking remote robotic surgery: Patient was in Africa; doctor was in Florida—ABC News WHO and Society of Robotic Surgery launch health innovation initiative to expand access to virtual care and telesurgery—WHO Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

This week, we look at new research on potassium optimization in patients with defibrillators, reducing antihypertensive therapy in nursing homes, an mRNA influenza vaccine, and belzutifan for rare neuroendocrine tumors. We review long QT syndrome and present a case of abnormal behavior and seizures in a young man. We also explore perspectives on primary care reform, tobacco cessation in HIV and tuberculosis care, corporate control in health care, and the simple power of compassion with ice cream.

Dr. Maria Janakos is a sports medicine physiatrist at NYU and a Clinical Assistant Professor at the NYU Grossman School of Medicine. She completed her residency at the University of Louisville and a Primary Care Sports Medicine Fellowship at Morristown Medical Center in New Jersey. Her clinical interests include concussion management, orthobiologics, musculoskeletal ultrasound, and event coverage. Dr. Janakos is actively involved in medical education at NYU, teaching medical students, residents, and fellows through lectures, hands-on training, and mentorship. At NYU, she is an active member of the NYU Concussion Center, where she regularly lectures on various concussion topics at both local and national levels. She specializes in the care of patients with acute concussions, treating individuals from adolescence through age 45. Part 2 The discussion included the following topics: challenges that patients face during the recovery period; factors determining treatment outcomes; preventing concussions; composition of the interdisciplinary treatment team; and the role of technology in treatment interventions.    

In this episode of The Health Advocates, host Steven Newmark breaks down what the recent federal government shutdown means for health care access and vulnerable patients. Then, he’s joined by Mahsa Pazokifard, a passionate patient advocate living with IgG4-related disease (IgG4-RD), a rare and often misunderstood autoimmune condition. Mahsa opens up about the challenges of getting diagnosed, how the disease has impacted her life and career, and why raising awareness is essential. Whether you’ve never heard of IgG4-RD or are living with a chronic illness yourself, this episode offers powerful insights into patient advocacy, rare disease awareness, and the human side of health care policy. To learn more about IgG4-Related Disease, visit: creakyjoints.org/igg4-rd-guide To learn more about vaccine recommendations and find reliable resources for patients, visit: ghlf.org/vaccines Contact Our Host Steven Newmark, Chief of Policy at GHLF: snewmark@ghlf.org A podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF. We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.org Listen to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

This week on Health Matters, Courtney talks with Dr. Warren Ng, a psychiatrist at New York Presbyterian and Columbia, and the Community Health Director for the Center for Youth Mental Health at NewYork-Presbyterian. Dr. Ng explains what makes narcissistic traits distinct from narcissistic personality disorders, and offers an in-depth explanation of the symptoms and management strategies for navigating relationships with narcissists, whether colleagues, friends, or family members. ___Dr. Warren Ng is a psychiatrist for children, adolescents, and adults with an interest in HIV, public psychiatry, and family issues. He is the Medical Director of Outpatient Behavioral Health and the Director of clinical services for the Division of Child and Adolescent Psychiatry at Columbia University Irving Medical Center and NewYork-Presbyterian/Morgan Stanley Children's Hospital. He is also the NYP Behavioral Health Service Line Clinical Innovation Officer. He is the President of the American Academy of Child and Adolescent Psychiatry and has been past president of the New York Council on Child and Adolescent Psychiatry. He served on the Assembly and the Council on Children, Adolescents, and Families at the American Psychiatric Association (APA).___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

On this accredited episode of NP Pulse: The Voice of the Nurse Practitioner®️, expert faculty Drs. Korey Hood and Kathryn Evans-Kreider explore the psychosocial challenges of living with type 1 diabetes, with a focus on how nurse practitioners can support patients experiencing diabetes distress. Faculty discuss practical strategies, such as using brief screening tools, adopting person-first and strengths-based language and tailoring care through shared decision-making. The conversation also highlights the impact of SDOH and the importance of integrating mental health awareness into routine diabetes management. This podcast is part of the Clinical Advantage Bootcamp: Type 1 Diabetes Management Certificate for Nurse Practitioners. Visit the AANP CE Center to view the other modules. A participation code will be provided at the end of the podcast — make sure to write this code down. Once you have listened to the podcast and have the participation code, return to this activity in the AANP CE Center. Click on the "Next Steps" button of the activity and: 1. Enter the participation code that was provided. 2. Complete the posttest. 3. Complete the activity evaluation. This will award your continuing education (CE) credit and certificate of completion. 1.0 CE will be available through Nov. 30, 2027.   Tool link : Diabetes_Billing_and_Coding_Toolkit.pdf   This collaboration between AANP and Danatech, an Association of Diabetes Care and Education Specialists (ADCES) initiative, is made possible thanks to grants from Helmsley Charitable Trust, Abbott and Medtronic.

Cameron is joined by Dr. Gina Maccarone, MD, a triple board-certified cosmetic surgeon, and they discuss her journey from general surgery to cosmetic surgery, including overcoming a non-compete agreement in Ohio. She emphasizes the importance of resilience, networking, and having a skilled legal team. She explains her marketing strategies, particularly leveraging social media and her website to build her brand.Cameron and Dr. Maccarone highlight the critical role of trust in aesthetic procedures, emphasizing how patients view these procedures as significant decisions regarding their physical appearance. They also discuss the importance of understanding patient concerns and expectations to ensure satisfactory outcomesListen In!Thank you for listening to this episode of Medical Millionaire!Takeaways:Trust is everything in aesthetic procedures.Patients are making significant decisions about their appearance.Understanding patient concerns is crucial for successful outcomes.Aesthetic procedures require a deep level of trust.The results of these procedures can greatly impact a patient's self-esteem.Communication between the patient and professional is vital.Patients often have high expectations for their results.The emotional aspect of aesthetic procedures cannot be overlooked.Professionals must be empathetic to patient needs.Building rapport with patients is essential for trust.Unlock the Secrets to Success in Medical Aesthetics & Wellness with "Medical Millionaire"Welcome to "Medical Millionaire," the essential podcast for owners and entrepreneurs inMedspas, Plastic Surgery, Dermatology, Cosmetic Dental, and Elective Wellness Practices! Dive deep into marketing strategies, scaling your medical practice, attracting high-end clients, and staying ahead with the latest industry trends. Our episodes are packed with insights from industry leaders to boost revenue, enhance patient satisfaction, and master marketing techniques.Our Host, Cameron Hemphill, has been in Aesthetics for over 10 years and has supported over 1,000 Practices, including 2,300 providers. He has worked with some of the industry's most well-recognized brands, practice owners, and key opinion leaders.Tune in every week to transform your practice into a thriving, profitable venture with expert guidance on the following categories...-Marketing-CRM-Patient Bookings-Industry Trends Backed By Data-EMR's-Finance-Sales-Mindset-Workflow Automation-Technology-Tech Stack-Patient RetentionLearn how to take your Medical Aesthetics Practice from the following stages....-Startup-Growth-Optimize-Exit Inquire Here:http://get.growth99.com/mm/

The occupation we have chosen is the most fulfilling job in the world. Cardiothoracic surgery has been the only career I have pursued as an adult, but I know that even without a meaningful comparison, my bold claim is correct. We have studied and practiced for years to acquire skills so that we can help to cure our patients or at least minimize their suffering. Yet, throughout all of our careers, having a patient succumb to their disease, or our attempt at treating their disease, is as much of a certainty as our own eventual mortality. Read this blog by Dr. Derek Serna-Gallegos on how to face your first patient death as a cardiothoracic surgeon.

Send us a textCardiologist Dr. Michael Koren is joined by a 35-year-old patient "Tucker" to walk through his cardiovascular numbers and explain what it all means. The doctor explores a lipid profile and an advanced lipid profile from top to bottom, explaining everything from how LDL is calculated to what hs-CRP measures. Along the way, they discuss how diet, exercise, supplements, and medications can affect these numbers, how the numbers relate to your risk of a cardiovascular event (like a heart attack or stroke) and what, if any, interventions should be taken. This real-world-example shows how complex the world of cardiology and lipids is and gives helpful, actionable information based on the numbers you might see. This podcast is not medical advice, and all personal situations should be discussed with your physician.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher Scientific, identifies the significant challenges in the US organ transplant system that must be addressed to meet the demand for organs.  Patient access to transplant care is hindered by geography, the need to match donors and recipients, and the threat of organ rejection. Living donations, particularly of kidneys and livers, are a solution to address the organ shortage, as organs from living donors often lead to better outcomes and can be scheduled to avoid damage caused by organ transportation. Tina explains, "So first of all, I would say that organ transplantation saves thousands of lives a year and gives patients with end-stage organ disease the ability to extend their lives meaningfully for many years. However, the organ transplant system in the US is not perfect, and it faces several real challenges. The most pressing challenge is a persistent imbalance between organ supply and demand, in that far more patients are in need of a lifesaving transplant than there are available organs, which leaves many patients waiting too long for a compatible organ or perhaps will never receive a compatible match. And unfortunately, for those patients left waiting, many get sicker, and often patients die while waiting on the wait list. So this gap in supply and demand is real, and it underscores the importance of living donation, which can help expand the pool of available organs and give patients a chance at the timely care that they need." "Another significant challenge is patient access to organ transplant care. For instance, in the weeks leading up to the transplant procedure and after the procedure, patients are often required to be living or situated near the hospital or the transplant center where the surgery is performed. This can pose a challenge to those who simply don't reside in areas where there are major transplant centers or who can't afford temporary housing. And that creates a socioeconomic inequity when it comes to access." #ThermoFisherScientific #Transplantation #OrganDonors #LivingDonation #HeartTransplant #OrganTransplants thermofisher.com Download the transcript here

Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher Scientific, identifies the significant challenges in the US organ transplant system that must be addressed to meet the demand for organs.  Patient access to transplant care is hindered by geography, the need to match donors and recipients, and the threat of organ rejection. Living donations, particularly of kidneys and livers, are a solution to address the organ shortage, as organs from living donors often lead to better outcomes and can be scheduled to avoid damage caused by organ transportation. Tina explains, "So first of all, I would say that organ transplantation saves thousands of lives a year and gives patients with end-stage organ disease the ability to extend their lives meaningfully for many years. However, the organ transplant system in the US is not perfect, and it faces several real challenges. The most pressing challenge is a persistent imbalance between organ supply and demand, in that far more patients are in need of a lifesaving transplant than there are available organs, which leaves many patients waiting too long for a compatible organ or perhaps will never receive a compatible match. And unfortunately, for those patients left waiting, many get sicker, and often patients die while waiting on the wait list. So this gap in supply and demand is real, and it underscores the importance of living donation, which can help expand the pool of available organs and give patients a chance at the timely care that they need." "Another significant challenge is patient access to organ transplant care. For instance, in the weeks leading up to the transplant procedure and after the procedure, patients are often required to be living or situated near the hospital or the transplant center where the surgery is performed. This can pose a challenge to those who simply don't reside in areas where there are major transplant centers or who can't afford temporary housing. And that creates a socioeconomic inequity when it comes to access." #ThermoFisherScientific #Transplantation #OrganDonors #LivingDonation #HeartTransplant #OrganTransplants thermofisher.com  Listen to the podcast here

'Heidi' records consultations and automatically creates draft clinical notes, referral letters, and follow-up summaries for doctors to review and approve. Dr Benjamin Pearson is Hawke's Bay's Chief Medical Officer spoke to Corin Dann.

Observational Cinematic Compulsion Disorder, or OCCD, is a common behavioral condition characterized by involuntary ocular fixation on a neighbor's in-flight audiovisual LCD display, even in the absence of accompanying auditory stimuli. Patients with OCCD exhibit vastly impaired concentration filtration, resulting in reflexive visual tracking of narrative cinematic sequences presented on adjacent personal screens during commercial air travel. The disorder is frequently associated with heightened situational distractibility, transient dissociative drift, and a paradoxical increase in attentional salience toward media not voluntarily selected by the patient. Management of OCCD involves admission to a 19th-century gothic asylum in upstate New York, with current clinical guidelines emphasizing electroconvulsive therapy administered on a daily basis, leading to a positive outcome of preemptive engagement with self-selected entertainment to mitigate cross-screen visual intrusion. This episode is brought to you by BetterHelp. Give online therapy and get on your way to being your best self at https://Betterhelp.com/BALD For a limited time get 40% off your first box PLUS get a free item in every box for life, by using promo code BALD at: https://Hungryroot.com/BALD To get simple, online access to personalized, affordable care for ED, Hair Loss, Weight Loss, and more, go to: https://Hims.com/BALD Find out why Nutrafol is the best-selling hair growth supplement brand by using promo code BALD at: https://Nutrafol.com The Holidays are here! Don't miss out on early Black Friday deals at Wayfair! Hurry, as the sale ends December 7th! For up to 70%off, head to: https://Wayfair.com Follow Trixie: @TrixieMattel Follow Katya: @Katya_Zamo To watch the podcast on YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://bit.ly/TrixieKatyaYT⁠ To check out our official YouTube Clips Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/TrixieAndKatyaClipYT⁠ Don't forget to follow the podcast for free wherever you're listening or by using this link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/thebaldandthebeautifulpodcast⁠ If you want to support the show, and get all the episodes ad-free go to: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thebaldandthebeautiful.supercast.com⁠ To check out future Live Podcast Shows, go to: ⁠⁠https://trixieandkatya.com/#tour⁠ To check out the Trixie Motel in Palm Springs, CA: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.trixiemotel.com⁠ Listen Anywhere! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://bit.ly/thebaldandthebeautifulpodcast⁠ Follow Trixie: Official Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.trixiemattel.com⁠ TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@trixie⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/trixiemattel⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/trixiemattel⁠ Twitter (X): ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/trixiemattel⁠   Follow Katya: Official Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.welovekatya.com⁠ TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@katya_zamo⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/welovekatya⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/katya_zamo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter (X): ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/katya_zamo⁠   #TrixieMattel #KatyaZamo #BaldBeautiful Learn more about your ad choices. Visit podcastchoices.com/adchoices

On a warm June afternoon in 1868, a 24-year-old woman accepted a glass of lemonade from her nurse at a Geneva boarding house. Within moments, her pupils dilated grotesquely, her heart pounded violently, and reality dissolved into nightmare. That glass of lemonade broke open one of Switzerland's most disturbing criminal cases.SEASON & EPISODE CONTEXTThis is Episode 9 of Foul Play Season 36: "Serial Killers in History," examining murderers from ancient times through the early 1900s. This season explores 15 cases spanning centuries and continents, revealing how serial murder predates modern criminology by millennia.THE CASE SUMMARYBetween 1865 and 1868, Marie Jeanneret worked as a private nurse in Geneva and surrounding areas of Switzerland, moving between respectable boarding houses and private hospitals. Everywhere she went, patients died under mysterious circumstances. Eleven-year-old children. Elderly widows. Entire families.Her method was both calculated and cruel. She used cutting-edge poisons for the 1860s—plant alkaloids like atropine from belladonna and morphine from opium poppies. These substances were so difficult to detect in corpses that she might never have been caught. She offered candy she called "princesses" to children. She served sweetened water to friends. She predicted deaths days before they happened—not because she had medical insight, but because she knew exactly when the poison would finish its work.When authorities finally exhumed the bodies in 1868, they found chemical signatures of murder in decomposing tissue. The trial revealed at least six confirmed murders and perhaps thirty attempted murders. But the verdict the jury reached would create one of criminal history's most profound paradoxes—her case helped abolish the death penalty in Geneva three years later.THE VICTIMSMarie Jeanneret's victims weren't random—they were people who trusted her completely during their most vulnerable moments:Marie Grétillat, 61, hired Jeanneret for what should have been a minor illness. She died in February 1867 after weeks of escalating agony.Sophie Juvet, 58, died in September 1867 at the Maison de Santé hospital where Jeanneret worked as a nurse.Jenny-Julie Juvet, Sophie's daughter, was only 11 years old. She loved candy and trusted the nurse who brought her special bonbons called "princesses." Before she died in January 1868, she begged her family not to let the nurse near her anymore. They thought she was delirious. She wasn't—she knew.Auguste Perrod (around 80), Louise-Marie Lenoir (72), Madame Hahn, Demoiselle Gay, Demoiselle Junod, Julie Bouvier, and Jacques Gros (Julie's father) all died under Jeanneret's care between 1867 and 1868.KEY CASE DETAILSTHE METHOD: Jeanneret used belladonna (deadly nightshade) and morphine as her primary weapons. Belladonna poisoning produces distinctive symptoms: grotesquely dilated pupils, rapid heartbeat, extreme light sensitivity, terrifying hallucinations, and eventually seizures and respiratory failure. Morphine suppresses breathing until victims simply stop inhaling—the death looks peaceful but is actually suffocation.As a nurse, she had legitimate access to these substances and professional cover for every action. She mixed poisons into sweet items—lemonade, sweetened water, candy—because sugar masks the bitter taste effectively. For some victims, she administered lower doses over time, creating slow declines that mimicked natural illness. For others, she used massive doses intended to kill quickly.THE BREAKTHROUGH: The case broke open when Marie-Catherine Fritzgès, 24, survived a belladonna poisoning in June 1868. Her doctor recognized the symptoms immediately and contacted authorities. Police searched Jeanneret's rooms and found bottles of belladonna extract, containers of morphine, and detailed nursing notes documenting every symptom, decline, and death—inadvertently documenting her own crimes.HISTORICAL CONTEXT & SOURCESThe 1860s represented a turning point in forensic medicine. Swiss medical examiners used groundbreaking techniques to test tissue samples for alkaloid compounds in exhumed bodies—finding chemical signatures consistent with belladonna and morphine poisoning. This case marked one of the first instances where forensic medicine played a crucial role in securing a conviction in Switzerland.The trial opened in Geneva in late 1868 with overwhelming evidence: poisoned bodies, survivors' testimony, bottles of poison, and Jeanneret's own nursing notes. On November 19, 1868, the jury returned a stunning verdict—guilty on all counts, but they recommended clemency. Instead of execution, Jeanneret received life imprisonment with hard labor.Three years later, in 1871, the Canton of Geneva abolished the death penalty. Jeanneret's case was cited as a key example—a jury had looked at overwhelming evidence of serial murder and chosen mercy over execution.RESOURCES & FURTHER READINGSwiss criminal history archives maintain extensive records of the Jeanneret case, including original trial transcripts and forensic reports that revolutionized poison detection methods. The case remains a standard reference in medical ethics courses throughout Europe, illustrating the catastrophic consequences of betrayed medical trust.The Geneva State Archives houses original court documents from the 1868 trial. Swiss forensic medicine institutes continue to study the case as a landmark example of early toxicology and the systematic safeguards developed in response to healthcare serial killers.RELATED FOUL PLAY EPISODESIf you found this episode compelling, explore other Foul Play cases involving Victorian-era poisoners and medical professionals who betrayed their sacred trust. Season 36 examines serial killers throughout history, from ancient Rome through the early 1900s, revealing how murder predates modern criminology and how society responded to unimaginable crimes.Each episode of Foul Play combines meticulous historical research with victim-centered storytelling, honoring those whose lives were taken while examining the criminals who took them.THE LEGACYMarie Jeanneret's crimes fundamentally transformed Switzerland's approach to medical safety and criminal investigation. The case exposed critical gaps in poison control, leading to strict measures including detailed record-keeping of sales and mandatory identification checks. Background checks for medical staff became more thorough, references were more carefully vetted, and supervision was enhanced throughout Europe.Perhaps most significantly, Jeanneret's case transformed public consciousness about the nature of evil. The idea that a healthcare professional could systematically murder patients while maintaining an appearance of respectability forced society to confront uncomfortable truths. The poisoner who took at least six lives became part of the movement that saved countless others from execution—the most paradoxical legacy imaginable.ABOUT FOUL PLAYFoul Play examines history's most compelling true crime cases with meticulous research and sophisticated storytelling. Hosts Shane Waters and Wendy Cee explore serial killers from ancient Rome through the early 1900s, focusing on victim-centered narratives that honor the dead rather than sensationalizing killers. Each episode combines atmospheric period detail with rigorous historical accuracy, transporting listeners to crimes that shaped criminal justice systems across centuries and continents.CONNECT WITH FOUL PLAYNew episodes release every Tuesday at 5:00 AM EST. Follow Foul Play on social media for behind-the-scenes research, historical context, and episode updates. Visit our website for complete episode archives, source lists, and additional resources about the cases we cover.CONTENT WARNINGThis episode contains detailed descriptions of poisoning, murder of children, and medical betrayal. Listener discretion is advised. If you or someone you know needs support, resources are available through crisis helplines and mental health services.Support this podcast at — https://redcircle.com/foul-play-crime-series/donationsAdvertising Inquiries: https://redcircle.com/brands

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Contributor: Aaron Lessen MD Educational Pearls:  Recent prospective randomized clinical trial assessed optimal head-of-bed positioning in patients with LVO 0º vs. 30º elevation Objective was to determine superiority of the two angles in stability prior to thrombectomy for LVO patients 45 patients randomized to the group with 0° head positioning and 47 patients randomized to the group with 30° head positioning Patients in the 30º group experienced worsening of NIHSS by 2 points or more Patients with head position at 0° showed score stability Hazard ratio 34.40; 95% CI, 4.65-254.37; P 

Every chiropractor wants patients who stay committed, not just until the pain fades, but for life. Dr. Tabor Smith reveals how a clear spinal-hygiene system turns that vision into reality. He shares the habits, structure, and mindset that help teams lead with certainty and patients take ownership of their care. This conversation dives into how simple daily systems can improve outcomes, prevent degeneration, and build real retention without adding complexity. You'll also learn how to empower your team with training that drives compliance, consistency, and conviction so your entire practice grows from purpose, not pressure.In this episode you will:Learn how to install a spinal-hygiene system that improves compliance and outcomes.Discover the four daily movements that protect the spine and increase patient buy-in.See how to connect hygiene education with patient retention and reactivation.Understand how to train your team to speak with certainty and consistency.Explore how a “dental model” for spinal care scales practice growth sustainably. Episode Highlights02:25 – Learn how a “tip-of-the-spear” mindset keeps chiropractors leading with conviction and purpose.03:45 – See why uniting passion with structure helps practices grow without chaos.05:42 – Understand why spinal hygiene fits every chiropractic technique and drives long-term retention.07:49 – Hear how the vision for spinal hygiene parallels dentistry's success in creating daily habits.08:36 – Discover how modern posture and technology accelerate spinal degeneration—even in teens.10:45 – Clarify the patient's role in lifelong spinal care versus the chiropractor's responsibility for checkups.15:13 – Learn what research reveals about how degeneration starts and how to reverse engineer prevention.19:37 – Explore how lifestyle habits influence 40 percent of spinal health outcomes.20:14 – Understand the “two-week rule” showing when immobilized joints begin arthritic change.24:31 – Introduce four core spinal-hygiene exercises every patient can safely perform at home.26:36 – Target C5 and L4-L5—the two areas most prone to degeneration—and how to protect them daily.27:50 – Use the “why” behind spinal hygiene to dramatically increase patient compliance.31:06 – Train tone, empathy, and certainty so your team converts through genuine care, not scripts.33:25 – Model home-care consistency across your team to raise accountability and results.36:36 – Simplify rollout with ready-made hygiene kits and see how the system runs itself.40:05 – Hear about the Certified Spinal Hygienist giveaway and how to enter for your full team.46:48 – Catch the closing reminder on how to email Dr. Tabor to join the draw before it closes.47:12 - Dr. Kale talks with Success Partners Dr. Andrew Wells and Dr. Chad Woolner from Simplified Functional Medicine about how chiropractors can add functional medicine without adding more work or complexity. They share the personal health challenges that led them into the field and why so many chiropractors struggle to deliver it on their own. They outline how their team-driven system keeps chiropractic central, protects a CEO's time, and creates strong clinical and financial results. It's a powerful look at what's possible when you simplify and step into your next level of impact. Resources MentionedLearn more about the TRP Remarkable Business Immersion - March 6 - 7, 2026 in Phoenix, AZ and March 20 - 21, 2026 in Brisbane, AUS - https://theremarkablepractice.com/upcoming-events/To learn more about the REM CEO Program, please visit:http://www.theremarkablepractice.com/rem-ceoFor more information about Simplified Functional Medicine please visit:  https://simplifiedfunctionalmedicine.com/Book a Strategy Session with Dr. Pete - https://go.oncehub.com/PodcastPCPrefer to watch? Catch the podcast on YouTube at: https://www.youtube.com/@TheRemarkablePractice1To listen to more episodes, visit https://theremarkablepractice.com/podcastor follow on your favorite podcast app.

Heavy Slow Resistance Training Combined with Patient Education in Patients with Gluteal Tendinopathy: A Feasibility Study Grigat JM, Kjeldsen T, Jørgensen SL, et al. Musculoskelet Sci Pract. Published online September 2025:103425. doi:10.1016/j.msksp.2025.103425 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest VALD MoveHealth - https://movehealth.me/ Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: "The Science of Selling Yourself Short" by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux  

Every Comic-Con, the guys have a few new friends who hang around, waiting for the right moment to jump on the mic. NO ONE ever waited as long (and as patiently) as new buddy Arturo, a man so prepared for NTS, that he brought his own chair. Yes, really.  -- #comedypodcast #humorpodcast #funnypodcast #darkhumor #podernfamily #RICC2025 #ComicCon #ricomiccon www.needlesstosaypodcast.com www.ntspodcastgear.com